<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55446">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02384330</url>
  </required_header>
  <id_info>
    <org_study_id>A-38-52120-188</org_study_id>
    <nct_id>NCT02384330</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin A Associated Costs in the Treatment of Upper Limb Spasticity Post Stroke</brief_title>
  <acronym>P_Dysport_CS</acronym>
  <official_title>Cost Determination Study For Different Botulinum Toxin A Preparations In The Treatment Of Upper Limb Spasticity Post-Stroke In Portugal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to estimate the costs of botulinum toxin A utilization in standard practice
      for the treatment of upper limb spasticity post-stroke in Portugal.

      It will consider the three most used locally available brands of botulinum toxin A which
      show similar efficacy and safety profiles thus making it relevant to understand if choosing
      between one or another brand can depend directly on economic factors.

      The study will estimate direct and indirect drug-associated costs as determinant variables
      for the price of each drug and the standard drug dose used in clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A comparison will be performed between direct costs associated with each therapeutic
      strategy and cost analysis assuming that quality of life values may be different between
      patients treated with each treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the cost of botulinum toxin utilization</measure>
    <time_frame>12 months</time_frame>
    <description>Direct resource utilization and costs of upper limb spasticity patients treated with BoNT-As, by product</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of work days missed due to spasticity</measure>
    <time_frame>12 months</time_frame>
    <description>Assessment of Absenteeism /loss of productivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carer time needed for patient assistance</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">57</enrollment>
  <condition>Upper Limb Spasticity Post-Stroke</condition>
  <arm_group>
    <arm_group_label>Dysport® (abobotulinumtoxinA)</arm_group_label>
    <description>Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botox® (onabotulinumtoxinA)</arm_group_label>
    <description>Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xeomin® (incobotulinumtoxinA)</arm_group_label>
    <description>Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital ambulatory patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with post-stroke upper limb spasticity

          -  Patients currently being treated with Dysport®, Botox® or Xeomin®

          -  Patients stabilized from a therapeutic point of view - with no switches of treatment
             in at least the 2 last administrations

          -  Patients who gave their written informed consent to participate.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar Fillat Boix, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Medicina de Reabilitação de Alcoitão</name>
      <address>
        <city>Alcabideche</city>
        <zip>2649-506</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C. H. A. - Hospital de Faro</name>
      <address>
        <city>Faro</city>
        <zip>8000-386</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C. H. T. M. A. D. - Unidade Hospitalar de Vila Real</name>
      <address>
        <city>Vila Real</city>
        <zip>5000-508</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 30, 2016</lastchanged_date>
  <firstreceived_date>March 4, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Muscle Spasticity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
